N@N

Haemacure Reports on Current Activities and Third Quarter 2009 FinancialResults

^{Published on 2009-09-14 09:39:47 - Market Wire}
 

 Financial Highlights (unaudited) Quarters ended July 31, 2009 July 31, 2008 ------------- ------------- Sales $ 15,390 $ 25,593 General and administrative expenses $ 579,598 $ 879,413 Research and development expenses $ 320,466 $ 978,680 Total expenses $ 824,634 $ 2,048,479 Net loss $ (798,852) $(2,022,886) Loss per share $(0.00) $(0.01) Weighted average number of shares outstanding 206,316,298 186,418,348 As at As at July 31, October 31, 2009 2008 ------- ---------- Cash and cash equivalents $ 303,626 $ 1,205,500 Investments $32,972 $ 3,398,496 Total assets $10,215,630 $13,033,252 Shareholders' equity $ 4,199,821 $ 8,818,586